Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial

被引：0
|
作者：
Nie, Run-Cong
Ding, Ya
Yuan, Shu-Qiang
Li, Yuan-fang
Wang, Wei
Chen, Yongming
Cai, Muyan
Sun, Xiao-wei
Weng, Desheng
Li, Dandan
Zhao, Jingjing
Chen, Xiaojiang
Guan, Yuanxiang
Ma, Luo
Qiu, Haibo
Zhou, Zhi-wei
Zhang, Xiao-Shi
Chen, Ying-bo
机构：
[1] Sun Yat Sen Univ, Sun Yat sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Melanoma & Sarcoma Med Oncol Unit, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Sun Ya Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4083
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study
    Jiao, Zuoyi, Sr.
    Zhou, Huinian, Sr.
    Yu, Zyuaun, Sr.
    Long, Bo
    Huang, Zeping
    Zhao, Da
    Wei, Dengwen
    Zhao, Xiaonin
    Jiang, Zebin
    Yang, Xiaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Concurrent Chemoradiotherapy plus Programmed Death-1 (PD-1) Blockade for Locally Advanced Cervical Cancer: Preliminary Results of a Single-Arm, Open -Label, Phase II Trial
    Xue, J.
    Shi, R.
    Ma, J.
    Liu, Z.
    Feng, G.
    Chen, Q. Q.
    Li, Y.
    He, Y.
    Ji, S.
    Shi, J.
    Zhu, X.
    Zhou, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E542 - E543
  • [33] Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer
    Liu, Xiaowen
    Li, Guichao
    Long, Ziwen
    Yin, Jiliang
    Zhu, Xiaodong
    Sheng, Weiqi
    Huang, Dan
    Zhu, Hui
    Zhang, Zhaozhen
    Cai, Hong
    Huang, Hua
    Zhao, Guangfa
    Zhou, Ye
    Zhang, Zhen
    Wang, Yanong
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (04) : 692 - 698
  • [34] AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
    Zhao, Yuanyuan
    Chen, Gang
    Chen, Jianhua
    Zhuang, Li
    Du, Yingying
    Yu, Qitao
    Zhuang, Wu
    Zhao, Yanqiu
    Zhou, Ming
    Zhang, Weidong
    Zhang, Yu
    Wan, Yixin
    Li, Wenting
    Song, Weifeng
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    ECLINICALMEDICINE, 2023, 62
  • [35] A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Rocca, Andrea
    Peruzzotti, Giulia
    Ghisini, Raffaella
    Viale, Giuseppe
    Veronesi, Paolo
    Luini, Alberto
    Intra, Mattia
    Pietri, Elisabetta
    Curigliano, Giuseppe
    Giovanardi, Filippo
    Maisonneuve, Patrick
    Goldhirsch, Aron
    Colleoni, Marco
    ANTI-CANCER DRUGS, 2006, 17 (10) : 1201 - 1209
  • [36] Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Shu-Qiang Yuan
    Run-Cong Nie
    Ying Jin
    Cheng-Cai Liang
    Yuan-Fang Li
    Rui Jian
    Xiao-Wei Sun
    Ying-Bo Chen
    Wen-Long Guan
    Zi-Xian Wang
    Hai-Bo Qiu
    Wei Wang
    Shi Chen
    Dong-Sheng Zhang
    Yi-Hong Ling
    Shao-Yan Xi
    Mu-Yan Cai
    Chun-Yu Huang
    Qiu-Xia Yang
    Zhi-Min Liu
    Yuan-Xiang Guan
    Yong-Ming Chen
    Ji-Bin Li
    Xiong-Wen Tang
    Jun-Sheng Peng
    Zhi-Wei Zhou
    Rui-Hua Xu
    Feng Wang
    Nature Medicine, 2024, 30 : 605 - 605
  • [37] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study.
    Zhang, Wen
    Du, Chun-Xia
    Jiang, Zhichao
    Sun, Yongkun
    Xie, Yibin
    Zhong, Yuxin
    Zhu, Yuelu
    Jiang, Liming
    Dou, Lizhou
    Xue, Qi
    Shao, Kang
    Gao, Shugeng
    Wang, Chengfeng
    Zhao, Dongbing
    Tian, Yantao
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
    Reynolds, John, V
    Preston, Shaun R.
    O'Neill, Brian
    Lowery, Maeve A.
    Baeksgaard, Lene
    Crosby, Thomas
    Cunningham, Moya
    Cuffe, Sinead
    Griffiths, Gareth
    Parker, Imelda
    Risumlund, Signe Lenora
    Roy, Rajarshi
    Falk, Stephen
    Hanna, George B.
    Bartlett, Frederick R.
    Alvarez-Iglesias, Alberto
    Achiam, Michael P.
    Nilsson, Magnus
    Piessen, Guillaume
    Ravi, Narayanasamy
    O'Toole, Dermot
    Johnston, Ciaran
    Mcdermott, Raymond S.
    Turkington, Richard C.
    Wahed, Shajahan
    Sothi, Sharmila
    Ford, Hugo
    Wadley, Martin S.
    Power, Derek
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 1015 - 1027
  • [39] Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial
    Xiao, Y.
    Cheng, H.
    Wang, L.
    Yang, L.
    Yu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S805 - S805
  • [40] A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer
    Peng, Jianjun
    Li, Yong
    Xiao, Jianjun
    Liu, Huaqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345